Octreotide

Acromegaly

Octreotide is a first-line medical therapy for acromegaly when surgery is not curative or not feasible. Octreotide LAR (10-40 mg IM monthly) normalizes GH and IGF-1 levels in approximately 50-70% of patients and produces clinically significant tumor shrinkage (>20% volume reduction) in 30-75% of patients depending on SSTR2 expression levels. Primary medical therapy (octreotide before surgery) has gained acceptance for debulking large macroadenomas. Predictors of response include high tumor SSTR2 expression and T2-hypointense MRI signal (Colao et al., 2011).

Carcinoid Syndrome

Octreotide effectively controls the flushing, diarrhea, and bronchoconstriction of carcinoid syndrome by suppressing serotonin and other vasoactive peptide secretion from midgut neuroendocrine tumors. Symptom control is achieved in 60-70% of patients. The LAR formulation provides consistent 28-day symptom control. Breakthrough symptoms are managed with supplemental subcutaneous octreotide (Rubin et al., 1999).

Neuroendocrine Tumor Growth Control

The landmark PROMID trial (2009) randomized patients with well-differentiated metastatic midgut NETs to octreotide LAR 30 mg monthly vs placebo, demonstrating significant prolongation of time to tumor progression (14.3 vs 6.0 months, HR 0.34) (Rinke et al., 2009). This established somatostatin analogs as antiproliferative agents, not merely symptom-control drugs, fundamentally changing NET management paradigms.

VIPomas and Other Secretory Tumors

Octreotide is the treatment of choice for VIP-secreting tumors causing watery diarrhea-hypokalemia-achlorhydria (WDHA/Verner-Morrison) syndrome. It controls diarrhea in the majority of patients and can be used as a bridge to surgery or as long-term palliation for unresectable disease. Similar efficacy is seen in glucagonomas, gastrinomas, and GRFomas (Nikou et al., 2005).

GI Bleeding

Octreotide (50 mcg IV bolus followed by 25-50 mcg/hr infusion) is standard adjunctive therapy for acute variceal bleeding in portal hypertension. It reduces portal pressure by decreasing splanchnic blood flow, and meta-analyses confirm improved bleeding control when combined with endoscopic therapy. It has largely replaced native somatostatin and vasopressin for this indication due to practical advantages and fewer side effects (Corley et al., 2001).

Somatostatin receptor pharmacology

Octreotide is a synthetic 8-amino-acid analog of somatostatin with a longer half-life and preferential affinity for somatostatin receptor subtypes 2 and 5 (SSTR2/SSTR5). Binding suppresses secretion of growth hormone, glucagon, insulin, and a range of gut hormones, and exerts antiproliferative effects on SSTR-expressing tumors. It is available as short-acting subcutaneous, long-acting-release (LAR) depot, and oral (permeation-enhanced) formulations.

• Preferential SSTR2/SSTR5 agonism suppressing GH and gut hormones
• Antiproliferative action on somatostatin-receptor-positive tumors
• Available as subcutaneous, LAR depot, and oral formulations

Neuroendocrine tumor therapy

Beyond symptom control of hormone hypersecretion, octreotide LAR was shown in the PROMID trial to significantly delay tumor progression in metastatic midgut NETs, shifting somatostatin analogs from purely symptomatic to antitumor therapy. SSTR expression also underpins somatostatin-receptor imaging (e.g., Ga-68 DOTATATE PET) and peptide receptor radionuclide therapy, for which octreotide-family peptides serve as targeting scaffolds.

• PROMID established antiproliferative benefit in midgut NETs
• SSTR targeting enables receptor imaging and radionuclide therapy
• Long-acting depot enables monthly dosing for chronic control